Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hls Therapeutics (TSE:HLS)
:HLS
Holding TSE:HLS?
Track your performance easily
HLS Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$3.00 - C$5.48
Previous CloseN/A
Volume4.75K
Average Volume (3M)58.38K
Market Cap
C$126.85M
Enterprise ValueC$188.55M
Total Cash (Recent Filing)$25.15M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Mar 13, 2025EPS Estimate
-0.13Last Dividend Ex-Date
Apr 27, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding31,793,047
10 Day Avg. Volume27,819
30 Day Avg. Volume58,377
Standard Deviation0.13
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.67
Price to Cash Flow (P/CF)9.70
P/FCF Ratio2.00
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda11.17
Forecast
1Y Price Target
C$9.50Price Target Upside138.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
HLS Therapeutics Inc News
PremiumCompany Announcements
HLS Therapeutics to Announce Q3 2024 Financial Results
PremiumCompany Announcements
HLS Therapeutics to Present at Global Investment Conference
PremiumCompany Announcements
HLS Therapeutics Reports Mixed Q2 Results and Strategic SalesPremiumCompany Announcements
HLS Therapeutics Expands Vascepa Coverage in Canada
PremiumCompany Announcements
HLS Therapeutics Schedules Q2 Financial Results Call
PremiumCompany Announcements
HLS Therapeutics Divests Royalty Interest, Updates GuidancePremiumCompany Announcements
HLS Therapeutics Shareholders Back Board and Auditors
PremiumCompany Announcements
HLS Therapeutics Boosts Treatment Adherence with Support ProgramsBulls Say, Bears Say
Bulls Say
Financial PerformanceThe company met adjusted EBITDA expectations despite reporting lower sales.
GuidanceHLS increased the lower end of its adjusted EBITDA guidance.
Quarterly Results2Q-2024 results were in line with expectations with no unexpected bumps.
Bears Say
Financial PerformanceHLS reported financial results that came in slightly below estimates and consensus sales.
Revenue GuidanceThe company has lowered its 2024 revenue guidance.
Year-Over-Year Revenue Decline2Q-2024 revenues were down 12% compared to 2Q-2023.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.51% Insiders
0.01% Mutual Funds
1.57% Other Institutional Investors
97.89% Public Companies and
Individual Investors
HLS FAQ
What was Hls Therapeutics’s price range in the past 12 months?
Hls Therapeutics lowest stock price was C$3.00 and its highest was C$5.48 in the past 12 months.
What is Hls Therapeutics’s market cap?
Hls Therapeutics’s market cap is C$126.85M.
When is Hls Therapeutics’s upcoming earnings report date?
Hls Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is in 50 days.
How were Hls Therapeutics’s earnings last quarter?
Hls Therapeutics released its earnings results on Nov 07, 2024. The company reported -C$0.216 earnings per share for the quarter, missing the consensus estimate of -C$0.18 by -C$0.036.
Is Hls Therapeutics overvalued?
According to Wall Street analysts Hls Therapeutics’s price is currently Undervalued.
Does Hls Therapeutics pay dividends?
Hls Therapeutics pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on Hls Therapeutics dividends here
What is Hls Therapeutics’s EPS estimate?
Hls Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Hls Therapeutics have?
Hls Therapeutics has 31,793,047 shares outstanding.
What happened to Hls Therapeutics’s price movement after its last earnings report?
Hls Therapeutics reported an EPS of -C$0.216 in its last earnings report, missing expectations of -C$0.18. Following the earnings report the stock price went up 8.824%.
Which hedge fund is a major shareholder of Hls Therapeutics?
Currently, no hedge funds are holding shares in TSE:HLS
---
HLS Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$9.50 (138.10% Upside)
C$9.50 (138.10% Upside)
Insider Transactions
Bought Shares
Worth C$174.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.48%
12-Months-Change
Fundamentals
Return on Equity
-24.49%
Trailing 12-Months
Asset Growth
-20.27%
Trailing 12-Months
Company Description
Hls Therapeutics
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada and the United States.
---
HLS Stock 12 Month Forecast
Average Price Target
C$9.50
▲(138.10% Upside)
Technical Analysis
Best Analysts Covering HLS
1 Year
1 Year Success Rate
12/32 ratings generated profit
1 Year Average Return
+7.05%
reiterated a buy rating 3 months ago
Copying David Martin PhD's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +7.05% per trade.
---